united states – Open MRTD http://openmrtd.org/ Fri, 18 Mar 2022 06:16:16 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://openmrtd.org/wp-content/uploads/2022/01/icon-2022-01-31T171458.103-150x150.png united states – Open MRTD http://openmrtd.org/ 32 32 New state revenues make Alaskans feel a little richer; Governor Calls for Large Permanent Fund Dividends | Local News https://openmrtd.org/new-state-revenues-make-alaskans-feel-a-little-richer-governor-calls-for-large-permanent-fund-dividends-local-news/ Fri, 18 Mar 2022 01:17:00 +0000 https://openmrtd.org/new-state-revenues-make-alaskans-feel-a-little-richer-governor-calls-for-large-permanent-fund-dividends-local-news/ The country united states of americaUS Virgin IslandsU.S. Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth ofCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People’s Socialist Republic ofAlgeria, People’s Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory south of 60 degrees S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People’s Republic […]]]>

]]>
SunPower: revenue stable after spin-off with Maxeon (NASDAQ: SPWR) https://openmrtd.org/sunpower-revenue-stable-after-spin-off-with-maxeon-nasdaq-spwr/ Tue, 15 Mar 2022 15:56:00 +0000 https://openmrtd.org/sunpower-revenue-stable-after-spin-off-with-maxeon-nasdaq-spwr/ Jonas Rönnbro/iStock via Getty Images Ahead of its analyst day on March 31, 2022, leading solar and energy service provider, SunPower Corporation (SPWR) plans to update investors on investments to improve the company’s customer services, particularly on the domestic solar front. Companies like Sunrun Inc. (RUN) and Sunnova Energy (NOVA) reportedly lost a combined $500 […]]]>

Jonas Rönnbro/iStock via Getty Images

Ahead of its analyst day on March 31, 2022, leading solar and energy service provider, SunPower Corporation (SPWR) plans to update investors on investments to improve the company’s customer services, particularly on the domestic solar front. Companies like Sunrun Inc. (RUN) and Sunnova Energy (NOVA) reportedly lost a combined $500 million in the first nine months of 2021. They used around $1.3 billion in cash in their operations in due to the rapid growth of solar installations. By the end of 2021, US home solar installations were expected to increase by more than 7% as the effect of the pandemic continued to wane. In addition, the Russian invasion of Ukraine has caused the price of crude oil and Brent oil to jump by more than 40% in the last 3 months.

Thesis

SunPower is still a buy despite the weather and COVID-19 challenges of 2020 and 2021 that sent the stock down 43.53% in the year-over-year price return analysis. For me, the exit of the business from light commerce, including the manufacture of solar panels by splitting with Maxeon Solar Technologies (MAXN) is a complement for the reintegration of the company. In addition, SunPower’s transformation into a renewable energy company focused on residential customers will be strategic for its long-term growth.

The Maxeon split

It’s no surprise that SunPower has diverged from solar panel manufacturing and instead focused on solar power distribution. Tianjin Zhonghuan Semiconductor (TZS) made possible the split with Maxeon Solar in the second quarter of 2020 by investing $298 million in the deal.

Maxeon solar panels on a roof

Solar Reviews

Since January 2021 (after the spin-off with Maxeon in August 2020), SunPower’s revenue increased by $198.7 million or 17.67%. Gross margin also increased by 32.14% while cash increased by over 111.77%. These fundamentals are impressive, but the solar energy company has yet to regain its dominance of previous years. Cash levels in January 2014 hit a high of $956.2 million, while in December 2014 revenue saw the biggest increase at $3.027 billion.

U.S. solar panel makers have had a tough time, especially after semiconductor supply issues hit the market at the onset of the COVID-19 pandemic. Ormat Technologies (ORA) is down 6.78% since March 2021 while revenue is down 5.98% in the year to December 2021.

Falling prices for returns from solar panel manufacturers

Looking for Alpha

In my list of the top five solar panel makers in the US, First Solar Inc. (FSLR) is down 8.65% over the past year, while SolarEdge Technologies (SEDG) is up 6.97% and NextEra Energy (NEE) gained 5.01% at the same time. .

With Maxeon, supply challenges in the solar industry can be minimized in the long term, especially with the entry of market leaders; TotalEnergies (TTE) and Tianjin Zhonghuan as majority shareholders. Total holds a 51.7% stake in SunPower and a 36.4% position in Maxeon.

SunPower’s intention in this spin-off is to expand its position in the North American distributed generation and storage market. In its fourth quarter 2022 earnings report, SunPower raised its 2022 EBITDA guidance to a range of $90 million to $110 million. The company, however, hinted at a $15 million reduction in guidance after selling its light commercial operations to Total.

SunPower’s deal to sell its commercial and industrial solutions business to TotalEnergies for $250 million was a tempting undertaking. In Q3 2021, SPWR lost $8 million due to C&I, and retaining that market would also prevent the company from fully divesting and focusing on the residential business.

Eyes will now be on TotalEnergies, which is looking to expand its distributed generation business in the United States. Overall, Total aims to support its B2B customers and support its sustainable development objectives (green energy). About this acquisition, Vincent Stoquart – Deputy CEO of TotalEnergies said:

This is another step in our development of renewable energy in the country, where we are aiming for 4 gigawatts of solar capacity by 2025.

Currently, TotalEnergies owns nearly 500 MW of distributed energy production. This acquisition will increase Total’s presence in the United States and help the company expand its annual capacity to more than 100 MW. With the deal expected to close in the second quarter of 2022, SunPower will use the proceeds to increase its digital offerings and reach more homeowners. The company was optimistic about increasing its investment in digital products to improve customer experience and operational efficiency.

Net income up for TotalEnergies

Looking for Alpha

Suffice it to say that TotalEnergies has benefited a lot from this agreement and more. In the past year, its net income has increased by more than 500%, while Maxeon’s has decreased by 18.73%, while SPWR is down by 108.73%.

Benefits for residential businesses

The Russian invasion of Ukraine also forced the Biden administration to ban the import of oil from Russia. WTI and Brent crude oil prices have gained over 40% in the last 3 months. About 700,000 barrels per day were imported from Russia by the United States in 2021, and this ban will deprive Russia of billions. Nevertheless, rising energy costs among American families will force the integration of renewable energy into residential areas.

SunPower outlined its plan to increase residential origination financing from 35% in 2021 to 45% in 2022. In doing so, the company aims to capture new fee income that was absent in previous transactions. Customers will now be able to access faster financing while helping dealers and sellers close deals faster.

This initiative is imperative given that the industry is growing at a modest pace. The residential solar market is expected to grow at a CAGR of 9.68% from 2021 to 2025. It is expected to reach $5.99 billion by 2025.

Residential solar market on the rise

PR News Feed

The US market is expected to make a 100% contribution with an additional growth rate of nearly 6%. In 2021, Houston-based solar giant Sunnova Energy grew its customer base by more than 81% to 195,400. That number was spread across 25 US states. The company’s residential solar power has reached 1.14 GW of generation capacity as it plans to reach 400,000 homes by the end of 2023.

After adding 13,000 customers in Q3 2021, SunPower currently has a customer base of up to 427,000 after seeing a 42% increase in Q4 2021. Residential gross margins hit a high of 20%, indicating the strength of this market. As the company enters 2022, its new home segment saw an increase of 66,000 new customers, +40% year-over-year. With the planned digital investment in 2022, adjusted EBITDA per customer (before investment) was $2,200.

SunPower’s management is also very confident about the success of the Blue Raven arm of its business. In early 2021, this retailer reported 3-year revenue growth of 268%. It was after the acquisition of Blue Raven in October 2021 that SunPower shifted its focus to residential customers. It was determined that more than 90% of Blue Raven’s customers are in 14 U.S. states where SunPower only had 5% of sales in Q3 2021. In essence, SPWR is looking to increase its presence in areas where the company had a minimal market share.

In my opinion, the transaction value of $165 million to acquire Blue Raven is affordable compared to its sale with TotalEnergies (at $250 million), the two are miles apart. Up to 1 million shares of Enphase Energy (ENPH) were used to finance this acquisition, indicating the strength of the solar market. Even after spending that amount, SunPower still had $127 million in unrestricted cash and an additional 2.5 million Enphase shares to use for future acquisitions and purposes.

Investors have benefited greatly from Enphase Energy, with the share price peaking at +2,800% in the 3 years to November 2021.

3-year review of Enphase and SunPower prices

Looking for Alpha

SunPower’s three-year price return hit a high of 380.96%, outperforming the S&P 500 at 59%. The CEO of SunPower has confirmed that the company has entered into a partnership agreement with Enphase until the first quarter of 2024.

The industry has other avenues for growth, including battery storage. SunPower announced that it has restarted sales of its SunVault storage systems by the third quarter of 2021. The systems will provide distributed storage that could offset distribution upgrades. Upgrades are becoming necessary even among non-solar customers such as electric vehicle owners.

In Q3 2021, the clean energy pipeline saw solar account for the largest share at 54%, onshore wind systems come next at 23%, offshore wind at 13% and battery storage is the last at 9%.

Risk

SunPower’s revenues since it spun off from Maxeon have yet to reach pre-pandemic levels. The company’s net losses in January 2022 increased by 107.87% to $37.4 million from a net profit of $475 million recorded in January 2021.

Legally, SunPower is involved in a securities class action lawsuit. Investors in the company reportedly lost their funds between August 3, 2021 and January 20, 2022, as a result of alleged securities fraud. A negative result, against SPWR, could have a negative impact on the stock price, although we expect this to be a short-term business.

Conclusion

The alluring power of solar technology has boosted the price performance of stocks such as Enphase and SunPower over the past two years. SunPower’s decision to focus on the residential market will help the company scale its digital and financial products toward growing its customer base. The company’s acquisition of Blue Raven is fundamental to establishing a dominant position in other markets as SunPower seeks to increase its long-term revenues. For these reasons, we are offering a buy rating for the stock.

]]>
The Corporate Finance Transformation Consulting Market Is Booming Globally https://openmrtd.org/the-corporate-finance-transformation-consulting-market-is-booming-globally/ Tue, 15 Mar 2022 07:14:06 +0000 https://openmrtd.org/the-corporate-finance-transformation-consulting-market-is-booming-globally/ “Global Consulting in corporate finance transformation Market Research Report 2022 »This research report offers Covid-19 outbreak study accumulated to offer the latest insights into the acute characteristics of the Corporate Finance Transformation Consulting market. This intelligence report includes investigations based on Current scenarios, historical records and future predictions. The report contains different market forecasts related […]]]>

“Global Consulting in corporate finance transformation Market Research Report 2022 »This research report offers Covid-19 outbreak study accumulated to offer the latest insights into the acute characteristics of the Corporate Finance Transformation Consulting market. This intelligence report includes investigations based on Current scenarios, historical records and future predictions. The report contains different market forecasts related to the market size, revenue, production, CAGR, consumption, gross margin, charts, graphs, pie charts, price, and other important factors. While emphasizing the major driving and restraining forces of this market, the report also offers a comprehensive study of the future market trends and developments. It also examines the role of major market players involved in the industry including their company overview, financial summary and SWOT analysis. He presents the 360 degrees overview of the industries competitive landscape. The market for consulting in the transformation of corporate finance is stable growth and CAGR is expected to improve over the forecast period.

Global Corporate Finance Transformation Consulting Market Segmentation
By Type, the Corporate Finance Transformation Consulting Market has been segmented into:
Consulting in strategic financial model
Shared Financial Model Consulting
Financial advice in Lean business management

By Application, the Corporate Finance Transformation Consulting Market has been segmented into:
BFSI
Health care
IT & Telecom
Manufacturing
Retail
Chemical
Energy and Utilities
Food and drink
Others

Major Key Players Covered in the Corporate Finance Transformation Consulting Market are:
PwC
Bath & Company
Boston Consulting Group
To Kearney
Accenture PLC
Deloitte
Ernest and Young
KPMG
McKinsey & Company
Mercier
FTI Council
ITConnect US
B2E advice
Mazars

Global Corporate Finance Transformation Consulting Market report provides you with in-depth insights insights, industry knowledge, market forecasts and analysis. The global corporate finance transformation consulting industry report also clarifies economic risks and environmental compliance. Global Corporate Finance Transformation Consulting Market report helps industry enthusiasts including investors and policy makers to make capital investments with confidence, develop strategies, optimize their business portfolio, innovate successfully and perform safely and sustainably.

Corporate Finance Transformation Consulting Market: Regional Analysis Includes:

  • Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)
  • Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
  • North America (United States, Mexico and Canada.)
  • South America (Brazil, etc)
  • The Middle East and Africa (GCC countries and Egypt.)

Main points covered in the table of contents:

  • Overview: Along with a broad overview of the global Corporate Finance Transformation Consulting market, this section provides an overview of the report to give an idea of ​​the nature and content of the research study.
  • Analysis of the strategies of the main players: Market players can use this analysis to gain a competitive advantage over their rivals in the corporate finance transformation consulting market.
  • Study on the main market trends: This section of the report offers a deeper analysis of recent and future market trends.
  • Market Forecast: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Corporate Finance Transformation Consulting market.
  • Regional Growth Analysis: All major regions and countries have been covered Corporate Finance Transformation Consulting Market report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.
  • Sector analysis: The report provides accurate and reliable forecasts of the market share of important segments of the corporate finance transformation consulting market. Market players can use this analysis to make strategic investments in the key growth pockets of the Corporate Finance Transformation Consulting Market.

Key questions answered by the report include:

  • What will be the market size and the growth rate in 2027?
  • What are the key factors driving the global Corporate Finance Transformation Consulting market?
  • What are the key market trends impacting the growth of the Global Corporate Finance Transformation Consulting Market?
  • What are the challenges of market growth?
  • Who are the key vendors in the Global Corporate Finance Transformation Consulting Market?
  • What are the market opportunities and threats faced by the vendors in the Global Corporate Finance Transformation Consulting Market?
  • Trending factors influencing the market shares of Americas, APAC, Europe and MEA.
  • What are the key findings of the five forces analysis of the Global Corporate Finance Transformation Consulting Market?

Contents
Chapter One: Presentation of the Report
1.1 Scope of the study
1.2 Key Market Segments
1.3 Players Covered: Ranking by Corporate Finance Transformation Consulting Revenue
1.4 Market Analysis by Type
1.4.1 Corporate Finance Transformation Consulting Market Size Growth Rate by Type: 2020 VS 2028
1.5 Market by Application
1.5.1 Corporate Finance Transformation Consulting Market Share by Application: 2020 VS 2028
1.6 Objectives of the study
1.7 years considered

Chapter Two: Growth Trends by Regions
2.1 Corporate Finance Transformation Consulting Market Outlook (2015-2028)
2.2 Corporate Finance Transformation Consulting Growth Trends by Regions
2.2.1 Corporate Finance Transformation Consulting Market Size by Regions: 2015 VS 2020 VS 2028
2.2.2 Corporate Finance Transformation Consulting Historic Market Share by Regions (2015-2020)
2.2.3 Corporate Finance Transformation Consulting Forecasted Market Size by Regions (2021-2028)
2.3 Industry Trends and Growth Strategy
2.3.1 Key Market Trends
2.3.2 Market Drivers
2.3.3 Market challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Corporate Finance Transformation Consulting Market Growth Strategy
2.3.6 Key Interviews with Key Corporate Finance Transformation Consulting Players (Opinion Leaders)

Chapter Three: Competition Landscape by Key Players
3.1 Major Corporate Finance Transformation Consulting Players by Market Size
3.1.1 Key Corporate Finance Transformation Consulting Players by Revenue (2015-2020)
3.1.2 Corporate Finance Transformation Consulting Revenue Market Share by Players (2015-2020)
3.1.3 Corporate Finance Transformation Consulting Market Share by Company Type (Tier One, Tier Two and Tier 3)
3.2 Corporate Finance Transformation Consulting Market Concentration Ratio
3.2.1 Corporate Finance Transformation Consulting Market Concentration Ratio
3.2.2 Top Chapter Ten: and Top 5 Companies by Corporate Finance Transformation Consulting Revenue in 2020
3.3 Corporate Finance Transformation Consulting Key Players Head office and Area Served
3.4 Key Players Corporate Finance Transformation Consulting Product Solution and Service
3.5 Date of Enter into Corporate Finance Transformation Consulting Market
3.6 Mergers and acquisitions, expansion plans

{A free data report (in the form of an Excel data sheet) will also be provided upon request with a new purchase.

Contact us:

The Web:www.qurateresearch.com
E-mail:[email protected]
Phone: USA – +13393375221

Follow us @

LinkedIn

Twitter

Note: In order to provide more accurate market forecasts, all our reports will be updated prior to delivery considering the impact of COVID-19

]]>
Corporate Finance Transformation Consulting Market 2022 | Forecast, prospects, development, growth, overview and demands of the global industry by 2029 https://openmrtd.org/corporate-finance-transformation-consulting-market-2022-forecast-prospects-development-growth-overview-and-demands-of-the-global-industry-by-2029/ Mon, 14 Mar 2022 12:33:50 +0000 https://openmrtd.org/corporate-finance-transformation-consulting-market-2022-forecast-prospects-development-growth-overview-and-demands-of-the-global-industry-by-2029/ “Global Consulting in corporate finance transformation Market Research Report 2022 »This research report offers Covid-19 outbreak study accumulated to offer the latest insights into the acute characteristics of the Corporate Finance Transformation Consulting market. This intelligence report includes investigations based on Current scenarios, historical records and future predictions. The report contains different market forecasts related […]]]>

“Global Consulting in corporate finance transformation Market Research Report 2022 »This research report offers Covid-19 outbreak study accumulated to offer the latest insights into the acute characteristics of the Corporate Finance Transformation Consulting market. This intelligence report includes investigations based on Current scenarios, historical records and future predictions. The report contains different market forecasts related to the market size, revenue, production, CAGR, consumption, gross margin, charts, graphs, pie charts, price, and other important factors. While emphasizing the major driving and restraining forces of this market, the report also offers a comprehensive study of the future market trends and developments. It also examines the role of major market players involved in the industry including their company overview, financial summary and SWOT analysis. He presents the 360 degrees overview of the industries competitive landscape. The market for consulting in the transformation of corporate finance is stable growth and CAGR is expected to improve over the forecast period.

Key Players of the Global Corporate Finance Transformation Consulting Market Covered Are:
To Kearney
FTI Council
Mercier
McKinsey & Company
Bath & Company
ITConnect US
Mazars
Accenture PLC
PwC
Deloitte
KPMG
Boston Consulting Group
Ernest and Young
B2E Consultant

On the basis of types, the Corporate Finance Transformation Consulting market from 2015 to 2025 is primarily split into:
Consulting in strategic financial model
Shared Financial Model Consulting
Financial advice in Lean business management

Based on applications, the Corporate Finance Transformation Consulting market from 2015 to 2025 covers:
BFSI
Health care
IT & Telecom
Manufacturing
Retail
Chemical
Energy and Utilities
Food and drink
Others

Global Corporate Finance Transformation Consulting Market report provides you with in-depth insights insights, industry knowledge, market forecasts and analysis. The global corporate finance transformation consulting industry report also clarifies economic risks and environmental compliance. Global Corporate Finance Transformation Consulting Market report helps industry enthusiasts including investors and policy makers to make capital investments with confidence, develop strategies, optimize their business portfolio, innovate successfully and perform safely and sustainably.

Corporate Finance Transformation Consulting Market: Regional Analysis Includes:

  • Asia Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia and Australia)
  • Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
  • North America (United States, Mexico and Canada.)
  • South America (Brazil, etc)
  • The Middle East and Africa (GCC countries and Egypt.)

Main points covered in the table of contents:

  • Overview: Along with a broad overview of the global Corporate Finance Transformation Consulting market, this section provides an overview of the report to give an idea of ​​the nature and content of the research study.
  • Analysis of the strategies of the main players: Market players can use this analysis to gain a competitive advantage over their rivals in the corporate finance transformation consulting market.
  • Study on the main market trends: This section of the report offers a deeper analysis of recent and future market trends.
  • Market Forecast: Buyers of the report will have access to accurate and validated estimates of the total market size in terms of value and volume. The report also provides consumption, production, sales, and other forecasts for the Corporate Finance Transformation Consulting market.
  • Regional Growth Analysis: All major regions and countries have been covered Corporate Finance Transformation Consulting Market report. The regional analysis will help market players to tap into unexplored regional markets, prepare specific strategies for target regions, and compare the growth of all regional markets.
  • Sector analysis: The report provides accurate and reliable forecasts of the market share of important segments of the corporate finance transformation consulting market. Market players can use this analysis to make strategic investments in the key growth pockets of the Corporate Finance Transformation Consulting Market.

Key questions answered by the report include:

  • What will be the market size and the growth rate in 2027?
  • What are the key factors driving the global Corporate Finance Transformation Consulting market?
  • What are the key market trends impacting the growth of the Global Corporate Finance Transformation Consulting Market?
  • What are the challenges of market growth?
  • Who are the key vendors in the Global Corporate Finance Transformation Consulting Market?
  • What are the market opportunities and threats faced by the vendors in the Global Corporate Finance Transformation Consulting Market?
  • Trending factors influencing the market shares of Americas, APAC, Europe and MEA.
  • What are the key findings of the five forces analysis of the Global Corporate Finance Transformation Consulting Market?

Contents
Chapter One: Presentation of the Report
1.1 Scope of the study
1.2 Key Market Segments
1.3 Players Covered: Ranking by Corporate Finance Transformation Consulting Revenue
1.4 Market Analysis by Type
1.4.1 Corporate Finance Transformation Consulting Market Size Growth Rate by Type: 2020 VS 2028
1.5 Market by Application
1.5.1 Corporate Finance Transformation Consulting Market Share by Application: 2020 VS 2028
1.6 Objectives of the study
1.7 years considered

Chapter Two: Growth Trends by Regions
2.1 Corporate Finance Transformation Consulting Market Outlook (2015-2028)
2.2 Corporate Finance Transformation Consulting Growth Trends by Regions
2.2.1 Corporate Finance Transformation Consulting Market Size by Regions: 2015 VS 2020 VS 2028
2.2.2 Corporate Finance Transformation Consulting Historic Market Share by Regions (2015-2020)
2.2.3 Corporate Finance Transformation Consulting Forecasted Market Size by Regions (2021-2028)
2.3 Industry Trends and Growth Strategy
2.3.1 Key Market Trends
2.3.2 Market Drivers
2.3.3 Market challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Corporate Finance Transformation Consulting Market Growth Strategy
2.3.6 Key Interviews with Key Corporate Finance Transformation Consulting Players (Opinion Leaders)

Chapter Three: Competition Landscape by Key Players
3.1 Major Corporate Finance Transformation Consulting Players by Market Size
3.1.1 Key Corporate Finance Transformation Consulting Players by Revenue (2015-2020)
3.1.2 Corporate Finance Transformation Consulting Revenue Market Share by Players (2015-2020)
3.1.3 Corporate Finance Transformation Consulting Market Share by Company Type (Tier One, Tier Two and Tier 3)
3.2 Corporate Finance Transformation Consulting Market Concentration Ratio
3.2.1 Corporate Finance Transformation Consulting Market Concentration Ratio
3.2.2 Top Chapter Ten: and Top 5 Companies by Corporate Finance Transformation Consulting Revenue in 2020
3.3 Corporate Finance Transformation Consulting Key Players Head office and Area Served
3.4 Key Players Corporate Finance Transformation Consulting Product Solution and Service
3.5 Date of Enter into Corporate Finance Transformation Consulting Market
3.6 Mergers and acquisitions, expansion plans

{A free data report (in the form of an Excel data sheet) will also be provided upon request with a new purchase.

Contact us:

The Web:www.qurateresearch.com
E-mail:[email protected]
Phone: USA – +13393375221

Follow us @

LinkedIn

Twitter

Note: In order to provide more accurate market forecasts, all our reports will be updated prior to delivery considering the impact of COVID-19.

]]>
Karyopharm appoints new Head of Investor Relations https://openmrtd.org/karyopharm-appoints-new-head-of-investor-relations/ Mon, 14 Mar 2022 11:00:00 +0000 https://openmrtd.org/karyopharm-appoints-new-head-of-investor-relations/ – Elhan WebbCFA, formerly of Rubius Therapeutics and Radius Health, named senior vice president of Investor Relationship – – Webb brings over 20 years of diverse international experience in investor relations, business development, investment analysis and portfolio management in healthcare and biotechnology – NEWTON, Mass., March 14, 2022 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), […]]]>

Elhan WebbCFA, formerly of Rubius Therapeutics and Radius Health, named senior vice president of Investor Relationship –

– Webb brings over 20 years of diverse international experience in investor relations, business development, investment analysis and portfolio management in healthcare and biotechnology –

NEWTON, Mass., March 14, 2022 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Elhan Webb as Senior Vice President of Investor Relations.

“Elhan brings to Karyopharm extensive experience with both sell-side and buy-side analysts, as well as a strong network of the financial and biotech investment community,” said Richard Paulson, Chairman and CEO of Karyopharm. “Elhan has a proven track record of building top-notch investor relations functions, and she will leverage this expertise to build awareness and understanding of Karyopharm’s strong portfolio, pipeline and vision for the future. We are excited to have him on the team.”

Ms. Webb brings over 20 years of experience to her new role. Most recently, she served as Vice President of Investor Relations at Rubius Therapeutics. Previously, she was Head of Investor Relations at Radius Health and Genfit. While at Roche Investor Relations, Ms. Webb led investor relations activities for Roche Diagnostics. She has also held business development positions at Roche Molecular Diagnostics and Morphochem. Earlier in her career, Ms. Webb spent more than a decade in Europe manage and direct healthcare investments in financial institutions such as BB Biotech-Bellevue Asset Management, Cantrade-UBS and Lombard Odier.

Ms. Webb holds a Masters of Business Administration from the University of Southern California and an undergraduate degree in economics Bogazici University in Istanbul, Turkey. She is also a CFA charter holder.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its inception, Karyopharm has been the industry leader in oral Selective Nuclear Export Inhibitor (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: the dysregulation of nuclear export. . XPOVIO® (selinexor), Karyopharm’s lead SINE compound and its first oral exportin 1 (XPO1) inhibitor, is approved in the United States and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a number of former U.S. territories and countries, including Europe and the UK (like NEXPOVIO®), China and Singapore. Karyopharm has a focused pipeline targeting several high unmet need cancer indications including endometrial cancer, myelodysplastic syndromes and myelofibrosis. For more information about our people, the science and the pipeline, please visit www.karyopharm.comand follow us on Twitter at @Karyopharm and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding the ability of selinexor or eltanexor to treat patients with multiple myeloma, diffuse large cell lymphoma B, tumors and other diseases; and expectations related to future clinical development and potential regulatory submissions of selinexor or eltanexor. These statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm’s control, which may cause actual events or results to differ materially from Karyopharm’s current expectations. For example, there can be no assurance that Karyopharm will be successful in obtaining regulatory approval for selinexor as first-line maintenance therapy after chemotherapy in patients with advanced or recurrent endometrial cancer; that Karyopharm will successfully commercialize XPOVIO; that regulators will grant confirmatory approval in the European Union based on the BOSTON study in adult patients with multiple myeloma; or that any of Karyopharm’s drug candidates, including selinexor and eltanexor, will successfully complete the necessary phases of clinical development or that development of any of Karyopharm’s drug candidates will continue. In addition, there can be no assurance that any positive development in the development or commercialization of Karyopharm’s pipeline of drug candidates will result in stock price appreciation. Management’s expectations and, accordingly, any forward-looking statements contained in this press release may also be affected by risks and uncertainties relating to a number of other factors, including the following: the risk that the COVID-19 pandemic 19 could disrupt Karyopharm’s business more severely than it currently anticipates, including negatively impacting XPOVIO’s sales, interrupting or delaying research and development efforts, affecting the ability to secure sufficient supply for the development and commercialization of selinexor or other product candidates, delaying ongoing or planned clinical trials, impeding the execution of business plans, anticipated regulatory milestones and timelines, or inconveniencing patients; commercial market adoption of XPOVIO, the timing and costs involved in commercializing XPOVIO or any Karyopharm drug candidate that receives regulatory approval; the ability to obtain and maintain regulatory approval for XPOVIO or any Karyopharm drug candidate that receives regulatory approval; results of Karyopharm’s clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, clinical trial site research review boards, and publication review bodies, including regarding the need for additional clinical studies; the ability of Karyopharm or its third party collaborators or assigns to fully perform their respective obligations under the applicable agreement and any future financial implications of such agreement; Karyopharm’s ability to enroll patients in its clinical trials; unforeseen cash requirements and expenditures; the development or regulatory approval of drug candidates by Karyopharm’s competitors for products or product candidates in which Karyopharm currently markets or develops; and Karyopharm’s ability to obtain, maintain and enforce patent and other intellectual property protections for any of its products or product candidates. These and other risks are described under “Risk Factors” in Karyopharm’s Quarterly Report on Form 10-K for the year ended. December 31, 2021which was filed with the Securities and Exchange Commission (SEC) on March 1, 2022, and in other filings that Karyopharm may file with the SEC in the future. All forward-looking statements contained in this press release speak only as of the date hereof and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. All other trademarks mentioned herein are the property of their respective owners.

SOURCE Karyopharm Therapeutics Inc.

]]>
Global Ignition Coil Market to Generate Larger Revenues During Forecast Period 2022-2028 – The Bite https://openmrtd.org/global-ignition-coil-market-to-generate-larger-revenues-during-forecast-period-2022-2028-the-bite/ Sun, 13 Mar 2022 21:18:28 +0000 https://openmrtd.org/global-ignition-coil-market-to-generate-larger-revenues-during-forecast-period-2022-2028-the-bite/ A report on the Global Ignition Coil Market was recently published by MarketsandResearch.biz. It presents a competent and detailed assessment of the current situation, focusing on essential factors, market strategies and successful development of key players. Additionally, the study adds a discussion of recent product developments. It offers an overview of future regional market shares […]]]>

A report on the Global Ignition Coil Market was recently published by MarketsandResearch.biz. It presents a competent and detailed assessment of the current situation, focusing on essential factors, market strategies and successful development of key players. Additionally, the study adds a discussion of recent product developments. It offers an overview of future regional market shares and an analysis of upstream and downstream sectors containing raw materials and suppliers, and machinery.

The study first introduces the basics of Ignition Coil: concepts, classifications, applications and industry overview; Product specifications; manufacturing processes; cost structures and raw materials. A granular analysis of industry dynamics, market share, and sales estimates is presented. The research reveals key factors influencing and driving growth market data and analysis.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/259171

The Ignition Coils business report study and key opportunities are as follows: Regional market penetration around the world is assessed for this business research. The market research examines the market potential of each geography in terms of CAGR, economic and financial aspects, customer spending habits, and industry supply and demand scenarios. Major advancements, innovations, mergers and acquisitions of organizations and agreements with other notable institutions have all been studied.

The organization involved

  • Bosch
  • Denso
  • Delphi
  • Tenneco (federal-tycoon)
  • BorgWarner
  • AcDelco
  • Hitachi
  • NGK
  • Eldor Company
  • Yura
  • Mitsubishi
  • SMP
  • SparkTronic
  • Electric Marshall
  • SO GOOD
  • electric diamond maker
  • Jiaercheng
  • KING-AUTO

The type segment includes:

The application segment includes:

Geographically, the report is split into

  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
  • South America (Brazil, Argentina, Colombia and rest of South America)
  • Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa and Rest of Middle East and Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/259171/global-ignition-coil-market-2022-by-manufacturers-regions-type-and-application-forecast-to-2028

Reasons to get the following report which will help you understand potential developments in Marketing Platforms, understand the real market scenario along with key industries, identify possible classes on the basis of comprehensive value examination and volume, current market trends, changing application solutions, and market landscapes can assist companies operating in the Ignition Coil Market.

Report customization:

This report can be customized to meet customer requirements. Please contact our sales team (sales@marketsandresearch.biz), who will ensure that you get a report tailored to your needs. You can also get in touch with our executives at 1-201-465-4211 to share your research needs.

Contact us
mark the stone
Business Development Manager
Call: 1-201-465-4211
E-mail: sales@marketsandresearch.biz
The Web: www.marketsandresearch.biz

]]>
Investor Relations Solutions Market Volume, 2026 Status, Growth, Opportunities – Investis Limited (Investis Digital), Dion Global Solutions, CB Information Services, Broadridge Financial Solutions, Investor Management Services and Allvue Systems https://openmrtd.org/investor-relations-solutions-market-volume-2026-status-growth-opportunities-investis-limited-investis-digital-dion-global-solutions-cb-information-services-broadridge-financial-solut/ Sun, 13 Mar 2022 10:13:34 +0000 https://openmrtd.org/investor-relations-solutions-market-volume-2026-status-growth-opportunities-investis-limited-investis-digital-dion-global-solutions-cb-information-services-broadridge-financial-solut/ The report is a holistic view of the world situation Investor Relations Solutions Market, available long-term investment opportunities and growth areas. In this regard, the report has conducted primary and secondary research methods as well as recorded individual experiences of industry leaders. Global Investor Relations Solutions Market insights are contributed by industry players and experts […]]]>

The report is a holistic view of the world situation Investor Relations Solutions Market, available long-term investment opportunities and growth areas. In this regard, the report has conducted primary and secondary research methods as well as recorded individual experiences of industry leaders. Global Investor Relations Solutions Market insights are contributed by industry players and experts in the field of the Global Investor Relations Solutions Market, including manufacturers, trade associations, agencies government, large corporations and other keyword industry stakeholders. The growth strategies implemented by incumbents and start-ups of the global Investor Relations Solutions market to stay ahead of the competitive landscape of the industry are detailed in the report. This report on the global Investor Relations Solutions market covers several important topics for the Investor Relations Solutions industry.

The Investor Relations Solutions market report profiles the following companies:

Allvue Systems
Broadridge Financial Solutions
CB information services
Dion Global Solutions
Investis Limited (Investis Digital)
Investor Management Services
IHS Markit
Pitchbook data
Nasda
Neuspera Medical
S&P Global
SigmaLogic
Tracxn Technologies
Vertalo SEZC
wealth block

Request a sample report: https://www.orbisresearch.com/contacts/request-sample/6459124?utm_source=SLP

Investor Relations Solutions market type includes:

Solution
Services

Investor Relations Solutions Market Applications:

Small and medium enterprises
Large companies

The corporate influencers driving the global investor relations solutions market and impacting the planning and execution of business strategy and corporate viability are studied in detail. Other topics covered in this report are the evolving role of clusters in the global Investor Relations Solutions market, manufacturing scenario, regulatory challenges, and research and development (R&D) trends. The report is a holistic view of the global Investor Relations Solutions market and the strategies that competitors are implementing to provide innovative products and services in various markets. The benefits of moving to the global platform and significant growth opportunities are presented in this report.

Investor Relations Solutions Market Report Highlights:

• The report provides valuable insights into existing and potential investors as well as opportunities available in the global Investor Relations Solutions market.
• The report studies the key industry trends, opportunities, and challenges that market players may face in the coming years.
• The role of key players in increasing the competitiveness of the market is described in the report.
• End user analysis is provided in the report and based on which market strategies are defined. Further, the market is studied at regional and country level.
• The report presents the drivers of the global Investor Relations Solutions market.
• The report provides tailor-made solutions to market players that help them overcome market challenges and sustain the ever-changing business environment.
• An in-depth understanding of the local business environment in the countries operating in the global Investor Relations Solutions market is provided in the report.
• The report studies the competitiveness framework of the global Investor Relations Solutions market, including supply chain and demand analysis, cost competitiveness, business climate, intellectual and political climate.

Investigate before accessing the report at: https://www.orbisresearch.com/contacts/enquiry-before-buying/6459124?utm_source=SLP

Why But This Investor Relations Solutions Market Report?

• The report presents the economic and trade situation of the Investor Relations Solution manufacturing companies across the world.
• Major trends affecting the industry along with the detailed examination of the sales channels in different Investor Relations Solutions market segments, employment trends, international business and related trade statistics, financial condition of the Manufacturers financial statements, future forecasts based on current data are given in the report.
• Customized report and analysis of Global Investor Relations Solutions Market commodity for each state or region is offered in the report.
• The current market situation of the Investor Relations Solutions industry in the selected countries and other important topics relevant to the countries and the market are detailed in the study.

About Us:

Orbis Research (orbisresearch.com) is a one-stop-shop for all your market research needs. We have an extensive database of reports from leading publishers and authors around the world. We specialize in delivering customized reports according to our clients’ requirements. We have complete information about our publishers and therefore are sure of the accuracy of the industries and verticals of their specialization. This helps our clients map their needs and we produce the perfect market research required for our clients.

Contact us:

Hector Costello
Senior Manager – Client Engagements
Central Highway 4144N,
Suite 600, Dallas,
Texas – 75204, USA
Telephone number: United States: +1 (972)-362-8199 | IND: +91 895 659 5155
Email ID: [email protected]

Buy the full report at: https://www.orbisresearch.com/contact/purchase-single-user/6459124?utm_source=SLP

]]>
Licensing revenue comes into play for Biopharma Co. https://openmrtd.org/licensing-revenue-comes-into-play-for-biopharma-co/ Sat, 12 Mar 2022 16:30:47 +0000 https://openmrtd.org/licensing-revenue-comes-into-play-for-biopharma-co/ Shares of Clearside Biomedical Inc. traded up 42% after the company released its financial results for Q4/21 and FY21 and provided an update regarding positive developments within the company , including receiving more than $20 million in milestone payments from its business development partner. After U.S. markets closed on Thursday, biopharmaceutical company Clearside Biomedical Inc. […]]]>

Shares of Clearside Biomedical Inc. traded up 42% after the company released its financial results for Q4/21 and FY21 and provided an update regarding positive developments within the company , including receiving more than $20 million in milestone payments from its business development partner.

After U.S. markets closed on Thursday, biopharmaceutical company Clearside Biomedical Inc. (CLSD:NASDAQ), which is engaged in developing treatments to preserve, improve and restore vision for people with serious diseases of the back of the eye in delivering therapies directly through the suprachoroidal space (SCS®), announced financial results for the fourth quarter and fiscal year 2021 ended December 31, 2021.

Clearside Biomedical President and CEO George Lasezkay, Pharm.D., JD said, “Our suprachoroidal injection platform is a proven approach to ocular drug delivery that offers potential advantages over other types of delivery… Following the approval and launch of XIPERE™, the first product approved for suprachoroidal delivery, there is a growing base of retina specialists trained in the use of our SCS Microinjector® exclusive. With over 1,200 clinical injections to date and six ongoing clinical trials using our technology, we have established our leadership in this area.

“Our lead development asset, CLS-AX, combines the targeting, compartmentalization and potential durability of suprachoroidal delivery with pan-VEGF inhibition of a potent tyrosine kinase inhibitor. We are making progress in OASIS, our ongoing Phase 1/2a trial of CLS-AX in patients with wet AMD. In the first two OASIS cohorts, CLS-AX was well tolerated with no serious adverse effects,” added Dr. Lasezkay.

Dr. Lasezkay explained that based on the positive safety data seen so far in the OASIS wet AMD study, the company will add a fourth cohort to the trial to explore a wider range of doses (escalation of dose) to be taken in a phase 2b clinical trial. The company plans to publish results from Cohorts 3 and 4 later this year and said it has begun planning its Phase 2b clinical trial with the aim of opening enrollment for the study by the end of the year 2022.

Clearside noted that an important recent development within the company was the U.S. Food and Drug Administration (FDA) approval of XIPERE™ (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment macular edema associated with uveitis in October 2021.

The company said it received a total of approximately $20 million in Q4/21 in non-dilutive funding related to the development, approval and pre-launch stages from its commercialization partners XIPERE, Bausch + Lomb and Arctic Vision. , Bausch + Lomb commercially launching sales in the United States in Q1/22.

The company added that its partner Arctic Vision had started dosing patients in its Phase 3 study of ARVN001 for the treatment of macular edema associated with uveitis and said this month it had also started dosing. dose patients with diabetic macular edema in a phase 1 trial which is also being conducted in China.

The company said in Q4/21 it recorded licensing and other revenue of $25.7 million, compared to just $11,000 in Q4/20. The company noted that the increase was primarily due to milestone payments earned by its licensing partners XIPERE in Q4/21 and included $5 million of deferred revenue from prior upfront payments received under its contract with Bausch. + Lomb.

The company reported that in Q4/21, it posted net income of $18.7 million, or $0.31 per share, compared to a net loss of $7.1 million, or $0.14. per share in Q4/20. The company attributed the substantial increase in net profit to higher licensing revenue received in Q4/21.

The company said that for FY21, licensing and other revenue increased $21.7 million to $29.6 million from $7.9 million in FY20. The company said mentioned that the substantial increase was the result of milestone payments received from XIPERE licensing partners.

The company said its overall R&D spending in fiscal 2021 increased by $3.5 million to $18.5 million from $15.1 million in fiscal 2020. Clearside noted that the additional expenses were attributed to costs associated with the company’s CLS-AX Phase 1/2a clinical trial.

The company reported that for fiscal 21, it had net income of $376,000, or $0.01 per share, compared to a net loss of $18.2 million, or $0.39 per share in during the year 20.

The company said it had $30.4 million in cash on its balance sheet as of December 31, 2021 and that with an additional $10 million raised in Q1 22 through a XIPERE pre-launch milestone payment , it is well funded in Q2 23.

Clearside is a biopharmaceutical company headquartered in Alpharetta, Georgia, focused on developing treatments via the suprachoroidal space (SCS®) that preserve and restore vision in people with severe back diseases of the back. eye. The company explained that “its SCS injection platform utilizes the company’s proprietary SCS Microinjector®, which enables an in-office, reproducible, non-surgical procedure for the targeted, compartmentalized delivery of a wide variety of therapies to macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.” The company states on its website that “it believes its proprietary suprachoroidal delivery platform has the potential to become a standard for delivering therapies to treat chorioretinal disease.”

The FDA approved XIPERE™ (triamcinolone acetonide injectable suspension) from Clearside for suprachoroidal use in October 2021. The Company’s development, commercial and collaborative pipeline includes treatments for wet AMD, diabetic macular edema, Therapeutic Biofactory/Hereditary Retinal Disease and Melanoma Ocular/Choroidal Oncology.

Clearside Biomedical started the day with a market capitalization of approximately $80.6 million with approximately 59.7 million shares outstanding and a short stake of approximately 2.1%. Shares of CLSD opened 37% higher on Friday at $1.85 (+$0.50, +37.04%) from Thursday’s closing price of $1.35. The stock traded between $1.71 and $2.14 per share and closed at $1.92 (+$0.57, +42.59%).

[NLINSERT]

Disclosures
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He himself or the members of his household hold shares in the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of the Streetwise Reports billboard: None. Click here for important information on referral fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is provided for informational purposes only and does not constitute a recommendation to buy or sell any securities.
4) The article does not constitute investment advice. Each reader is encouraged to consult their financial professional and any action taken by a reader as a result of the information presented here is their own responsibility. By opening this page, each reader accepts and consents to the full Streetwise Reports Terms of Service and Legal Notice. This article is not an investment solicitation. Streetwise Reports does not provide general or specific investment advice and information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the activities, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or their family members, as well as those interviewed for articles and interviews on the site, may take a long or short position in the titles mentioned. Directors, officers, employees or members of their immediate family are prohibited from making purchases and/or sales of such securities on the open market or otherwise from the time of the decision to publish an article until three days working days after the publication of the article. The foregoing prohibition does not apply to articles that, in substance, merely restate previously published company announcements.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed healthcare professionals. Readers should always contact their healthcare professionals for medical advice.

]]>
Allison Transmission: Q4 2021 Investor Relations Overview https://openmrtd.org/allison-transmission-q4-2021-investor-relations-overview/ Mon, 07 Mar 2022 21:41:28 +0000 https://openmrtd.org/allison-transmission-q4-2021-investor-relations-overview/ Investor Relations Presentation Fourth Quarter 2021 (Published March 7, 2022) Safe Harbor Statement The following information contains, or may be deemed to contain, “forward-looking statements” (as defined in the United States Private Securities Litigation Reform Act of 1995). The words “believe”, “expect”, “anticipate”, “intend”, “estimate” and other […]]]>







Investor Relations Presentation

Fourth Quarter 2021 (Published March 7, 2022)

Safe Harbor Statement

The following information contains, or may be deemed to contain, “forward-looking statements” (as defined in the United States Private Securities Litigation Reform Act of 1995). The words “believe”, “expect”, “anticipate”, “intend”, “estimate” and other expressions which are predictions or indicate future events and trends and which do not relate historical matters not identify forward-looking statements. You should not place undue reliance on these forward-looking statements. Although forward-looking statements reflect the good faith beliefs of management, forward-looking statements should not be relied upon because they involve known and unknown risks, uncertainties and other factors, which may cause results, actual performance or achievements differ materially from anticipated future results. , performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements speak only as of the date they are made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to: the duration and spread of the COVID-19 pandemic, including new virus variants and the timing and availability of vaccines and reminders, mitigation efforts by government agencies and the general public, and the overall impact of such an outbreak on economic conditions, financial market volatility and our business, including, but not limited thereto, the operations of our manufacturing and other facilities, the availability of labor, our supply chain, our distribution processes and the demand for our products and the corresponding impacts on our net sales and flows cash ; increased costs, disruption of supply or shortage of labour, freight, raw materials or components used to manufacture or transport our products or those of our customers or suppliers, including as a result of the pandemic of COVID-19; our participation in competitive markets; our ability to prepare for, respond to and successfully achieve our objectives related to technological and market changes, competitive threats and changing customer needs, including with respect to hybrid electric and fully electric utility vehicles ; the highly cyclical industries in which some of our end users operate; the uncertainty of the global regulatory and business environments in which we operate; the concentration of our net sales in our top five customers and the loss of one of them; failure of markets outside of North America to increase adoption of fully automatic transmissions; the success of our research and development efforts, the outcome of which is uncertain; US and foreign defense spending; risks associated with our international operations, including increased trade protectionism; general economic and industrial conditions; the discovery of defects in our products, resulting in delays in the launch of new models, recall campaigns and/or increased warranty costs and reduced future sales or damage to our brand and reputation; our ability to effectively identify, complete and integrate acquisitions and collaborations; labor strikes, work stoppages or similar labor disputes, which could significantly disrupt our business or that of our major customers or suppliers; and risks related to our indebtedness.

Allison Transmission cannot assure you that the assumptions made in preparing any of the forward-looking statements will prove to be correct or that the long-term financial objectives will be achieved. All forward-looking statements included in this presentation speak only as of the date on which they were made, and Allison Transmission undertakes no obligation to publicly update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. In particular, Allison Transmission cautions you not to place undue importance on certain forward-looking statements relating to potential growth opportunities, long-term financial goals, or the value we currently place on certain tax attributes set forth herein. Actual results may differ materially from these statements.

Allison Transmission’s business is subject to numerous risks and uncertainties, which could cause future results of operations to differ materially from those presented herein. Important factors that could cause actual results to differ materially are discussed in Allison Transmission’s Annual Report on Form 10-K for the year ended December 31.2021.

Allison Transmission at a Glance

  • Leading designer and manufacturer of propulsion solutions for commercial and defense vehicles
    • The world’s largest manufacturer of means and heavy duty automatic transmissions
    • A leader and established supplier of commercial electrified propulsion systems
  • Premier brand, delivering superior performance frequently specified by end users
    • Premium price component
    • Differentiated technology
    • Reduced total cost of ownership
  • Well positioned for revenue and earnings growth
    • Later adoption outside North America
    • Expand the addressable market
    • Funded growth opportunities in an asset-light business model
  • Strong cash generation and well-defined capital allocation policy

Allison Transmission at a Glance

2021 net sales by end market

Rooms,

Support

Equipment

and other

22%

Outside

North America

Off road

3%

Outside

North America

On the highway

16%

Defense North

8% America

2021 net sales: $2.4 billionOff road

2%

North

America

On the highway

49%

This is an excerpt from the original content. To continue reading it, go to the original document here.

Warning

Allison Transmission Holdings Inc. published this content on March 07, 2022 and is solely responsible for the information contained therein. Distributed by publicunedited and unmodified, on March 07, 2022 21:40:11 UTC.

Public now 2022

All news about ALLISON TRANSMISSION HOLDINGS, INC.

Analyst Recommendations for ALLISON TRANSMISSION HOLDINGS, INC.

2022 sales 2,709 million

2022 net income 509M

Net debt 2022 2,319 million

PER 2022 ratio 7.98x
2022 return 1.89%
Capitalization 4,001 million
4,001 million
EV / Sales 2022 2.33x
EV / Sales 2023 2.12x
# of employees 3,400
Floating 99.1%

Chart ALLISON TRANSMISSION HOLDINGS, INC.


Duration :

Period :




Allison Transmission Holdings, Inc. Technical Analysis Chart |  MarketScreener

Trends in Technical Analysis ALLISON TRANSMISSION HOLDINGS, INC.

Short term Middle term Long term
Tendencies Neutral Bullish Neutral



Evolution of the income statement

To sell

To buy

Medium consensus HOLD
Number of analysts 11
Last closing price

$40.90

Average target price

$45.56

Average Spread / Target 11.4%


]]>
Kroll Corporate Finance advised Classic Design on its sale to a portfolio company of Crestview Partners https://openmrtd.org/kroll-corporate-finance-advised-classic-design-on-its-sale-to-a-portfolio-company-of-crestview-partners/ Fri, 04 Mar 2022 11:47:48 +0000 https://openmrtd.org/kroll-corporate-finance-advised-classic-design-on-its-sale-to-a-portfolio-company-of-crestview-partners/ On March 1, 2022, Crestview Partners (“Crestview”), a leading private equity firm, announced that its recently created automation solutions platform had completed the acquisition of Classic Design (“Classic” or the “ Company”), a Troy, Michigan provider of automation design and systems integration. Following the acquisition of JMP Solutions, Inc. (“JMP”) in August 2021, Classic is […]]]>

On March 1, 2022, Crestview Partners (“Crestview”), a leading private equity firm, announced that its recently created automation solutions platform had completed the acquisition of Classic Design (“Classic” or the “ Company”), a Troy, Michigan provider of automation design and systems integration. Following the acquisition of JMP Solutions, Inc. (“JMP”) in August 2021, Classic is the second acquisition as part of Crestview’s strategy to create a market-leading global automation solutions provider.

Kroll’s Business Services M&A Advisory acted as exclusive financial advisor to Classic Design on the transaction.

About Classic Design
Founded in 1974, Classic is an end-to-end designer, developer and integrator of custom automation solutions for automotive and defense customers. Headquartered in Troy, Michigan, with a global footprint in the United States and India and a strong heritage of engineering excellence, Classic is an established and innovative partner capable of delivering custom solutions across diverse systems and applications. Hall Render LP served as legal counsel to Classic. The Doescher Group provided additional support to company management in connection with the transaction.

About JMP Solutions, Inc.
Founded in 1987, JMP is an automation systems integrator providing solutions to various industrial and consumer end markets. It designs, engineers and integrates hardware and software to automate its customers’ manufacturing, production and distribution facilities. Headquartered in London, Ontario, with an established North American footprint consisting of 15 offices in the United States and Canada, JMP’s multi-geographic branch model gives it a strategic advantage over smaller sub-regional competitors, enabling it to provide focused, local support while growing with its best-in-class customer base across geographies and applications.

About Crestview Partners
Founded in 2004, Crestview is a value-oriented, middle-market focused private equity firm. The firm is based in New York and manages funds with approximately $10 billion in total capital commitments. The company is led by a group of partners who have complementary experience and distinguished backgrounds in private equity, finance, operations and management. Crestview has seasoned investment professionals who focus on investment research and management in each of the firm’s specialty areas: industrials, media and financial services.

]]>